Arbutus Biopharma is a publicly-traded (NASDAQ:ABUS) biopharmaceutical company dedicated to discovering, developing and commercializing a cure for patients suffering from chronic hepatitis B infection, a disease of the liver caused by hepatitis B virus (HBV). We are developing a portfolio of drug candidates with multiple mechanisms of action that we believe will result in a combination therapy that will transform the HBV treatment landscape and cure hepatitis B virus disease. Source
No articles found.
Gulf Chronic Care, Inc. was established specifically to address the diabetic epide...
Gulf Chronic Care, Inc. was established specifi...
CHF Solutions is focused on improving the quality of life for patients suffering f...
CHF Solutions is focused on improving the quali...
Valeritas is a commercial-stage medical technology company focused on improving he...
Valeritas is a commercial-stage medical technol...
Aurinia is a late clinical stage biopharmaceutical company focused on developing a...
Aurinia is a late clinical stage biopharmaceuti...
Merck KGaA, Darmstadt, Germany, a leading science and technology company, operates...
Merck KGaA, Darmstadt, Germany, a leading scien...
Benitec is a biotechnology company developing a proprietary therapeutic technology...
Benitec is a biotechnology company developing a...
Spring Bank is a clinical-stage biopharmaceutical company engaged in the discovery...
Spring Bank is a clinical-stage biopharmaceutic...
Join the National Investor Network and get the latest information with your interests in mind.